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Background. Candida species are among the most frequent causative agents of health care–associated bloodstream infections, 
with mortality >40% in critically ill patients. Specific populations of critically ill patients may present peculiar risk factors related to 
their reason for intensive care unit admission. The primary objective of the present study was to assess the predictors of candidemia 
after open heart surgery.
Methods. This retrospective, matched case–control study was conducted in 8 Italian hospitals from 2009 to 2016. The primary 
study objective was to assess factors associated with the development of candidemia after open heart surgery.
Results. Overall, 222 patients (74 cases and 148 controls) were included in the study. Candidemia developed at a median time 
(interquartile range) of 23 (14–36) days after surgery. In multivariable analysis, independent predictors of candidemia were New York 
Heart Association class III or IV (odds ratio [OR], 23.81; 95% CI, 5.73–98.95; P < .001), previous therapy with carbapenems (OR, 
8.87; 95% CI, 2.57–30.67; P = .001), and previous therapy with fluoroquinolones (OR, 5.73; 95% CI, 1.61–20.41; P = .007). Crude 
30-day mortality of candidemia was 53% (39/74). Septic shock was independently associated with mortality in the multivariable 
model (OR, 5.64; 95% CI, 1.91–16.63; P = .002). No association between prolonged cardiopulmonary bypass time and candidemia 
was observed in this study.
Conclusions. Previous broad-spectrum antibiotic therapy and high NYHA class were independent predictors of candidemia in 
cardiac surgery patients with prolonged postoperative intensive care unit stay.
Keywords.  bloodstream infection; Candida; cardiac surgery; postoperative complications.
In modern hospitals, many open heart surgical interventions 
are performed every day. Although cardiac surgery techniques 
have improved considerably over the last few years, a wide 
array of systemic and local infectious complications associ-
ated with these procedures have been reported [1, 2]. They are 
mainly local complications (eg, sternal wound infections), and 
overall bacterial etiology predominates [3, 4]. However, patients 
undergoing open heart surgery may also develop Candida 
bloodstream infections [5, 6].
Candida bloodstream infection (candidemia) has been asso-
ciated with increased morbidity and mortality in critically ill 
patients [7–19], and various general risk factors (eg, admin-
istration of broad-spectrum antibiotics, prolonged length of 
hospital stay, presence of a central venous catheter) have been 
extensively characterized [20–23]. Nonetheless, specific popu-
lations of critically ill patients may present additional peculiar 
risk factors related to their medical or surgical reasons for in-
tensive care unit (ICU) admission [6, 23–27]. Therefore, we 
conducted a case–control study in 8 hospitals in Italy to assess 
the predictors of candidemia after open heart surgery.
METHODS
Study Design and Objectives
The present observational, retrospective case–control study 
was conducted in 8 Italian centers located in 7 different 
applyparastyle “fig//caption/p[1]” parastyle “FigCapt”
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Italian regions. The study period was from January 1, 2009, to 
December 31, 2016. All patients who developed candidemia 
during the study period and during the ICU stay after open 
heart surgery were included as cases. Two controls without 
candidemia were matched to each case by the following cri-
teria: (i) center; (ii) date of open heart surgery (±1 month); (iii) 
time at risk. For cases, time at risk was defined as the number 
of days elapsed from surgery to the onset of candidemia (ie, the 
day when the first blood culture positive for Candida spp. was 
drawn). For controls, time at risk was defined as the number of 
days elapsed from surgery to hospital discharge or in-hospital 
death. To avoid scarce fulfillment of the matching criterion, 
we arbitrarily set the time at risk in controls to be equal to or 
longer than the time at risk in cases minus 5 days. Cases were 
included in the study only once, at the time of the first episode 
of candidemia after open heart surgery.
The primary study objective was to assess factors associated 
with the development of postoperative candidemia. The assess-
ment of predictors of crude mortality within 30 days after the 
onset of candidemia in cases was a secondary study objective. 
The study was approved by the ethical committee of the coor-
dinating center (Ethical Committee of Liguria Region, registry 
number 320REG2017). The other participating centers followed 
the local ethical requirements.
Data Collection
The following baseline data (preoperative and peri/
intraoperative variables) were retrospectively collected from 
medical records and laboratory databases of the participating 
hospitals: age, gender, diabetes (defined as any preopera-
tive diagnosis of diabetes mellitus requiring treatment), New 
York Heart Association (NYHA) class of heart failure, pre-
operative serum creatinine >200  μmol/L, chronic obstructive 
pulmonary disease (COPD; defined as long-term use of bron-
chodilators or steroids for lung disease), history of immuno-
suppression (defined as 1 or more of the following: solid organ 
transplantation, malignancy, neutropenia [absolute neutro-
phil count <1000 cells/mm3], HIV infection, chemotherapy 
within 45 days before surgery, therapy with ≥10 mg of pred-
nisone or its equivalent per day for >14 days before surgery), 
Charlson Comorbidity Index [28], peripheral vascular disease 
(defined as ≥1 of the following: carotid occlusion or >50% ste-
nosis, claudication, amputation for arterial disease, previous or 
planned intervention on the abdominal aorta, carotids, or limb 
arteries), preoperative stroke (defined as any focal or global 
neurological syndrome caused by ischemia or hemorrhage 
not resolving within 24 hours), previous acute myocardial in-
farction (within 3  months), left ventricular ejection fraction 
(LVEF), EuroSCORE II [29], type of open heart surgery (cat-
egorized as isolated coronary artery bypass surgery, isolated 
valvular surgery, surgery of thoracic aorta, or other/combined 
procedures), preoperative mechanical ventilation, pacemaker 
implantation, cardiopulmonary bypass (CPB) time in minutes, 
aortic cross-clamp time in minutes, sequential organ failure as-
sessment (SOFA) score at the time of surgery [30], need for 
peri/intraoperative blood transfusions.
The following data were also collected over the duration 
of the time at risk for candidemia in both cases and controls 
(postoperative variables): presence of central venous catheter 
for >48 hours, receipt of total parenteral nutrition for >48 
hours, hemodialysis therapy for >48 hours, administration of 
broad-spectrum antibiotics for >48 hours, Candida coloni-
zation (defined as isolation of Candida spp. from nonsterile 
sites in absence of signs and symptoms of infection), bacte-
rial bloodstream infections (defined as isolation of bacteria 
from blood in presence of signs and symptoms of infections, 
at least 2 positive cultures were required for coagulase-negative 
staphylococci).
The following data were also collected for cases (candidemia-
related variables): species of Candida isolated from blood, 
presence of septic shock at the time of candidemia (according 
to Sepsis-3 criteria [31]), removal of central venous catheter 
within 48 hours after the onset of candidemia, administra-
tion of antifungal therapy within 48 hours after the onset of 
candidemia.
Microbiology
Candida spp. were identified using the VITEK 2 automated 
system (bioMérieux, Marcy l’Etoile, France) or by MALDI-
TOF mass spectrometry (bioMérieux, Marcy l’Etoile, France, or 
Bruker Daltonik, Bremen, Germany), according to the standard 
laboratory diagnostic procedures adopted in the different 
participating centers.
Statistical Analysis
The primary study analysis was the identification of factors 
associated with the development of candidemia after open 
heart surgery. To this aim, demographic and clinical variables 
were first tested for their association with the dependent var-
iable (development of candidemia) in univariable conditional 
logistic regression models for matched pairs/sets, with strata 
composed by sets of single cases and their 2 matched con-
trols [32]. Then, variables associated with the development 
of candidemia in univariable comparisons (P < .05) were in-
cluded in an initial multivariable, conditional logistic regres-
sion model for matched pairs/sets and further selected for the 
final multivariable model by means of a stepwise backward 
procedure. A secondary study analysis was the identification of 
factors associated with crude 30-day mortality in candidemia 
cases. To this aim, we employed univariable and multivariable 
comparisons as for the primary analysis, with the exception of 
using unconditional logistic regression models. The analyses 
were performed using SPSS Statistics, version 21.0 (IBM Corp., 
Armonk, NY, USA).
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RESULTS
Overall, 222 patients were included in the study (74 cases and 
148 controls). Strict application of matching criteria was pos-
sible for 56% of controls (83/148). Owing to the absence of 
other controls fulfilling all 3 matching criteria, the remaining 
44% (65/148) were selected as those with the nearest date of 
surgery (with respect to cases) outside the matching period (ie, 
beyond ± 1 month) but still fulfilling the matching criteria for 
center and time at risk.
During the study period, 36 476 open heart surgery pro-
cedures were performed in the participating centers. The 
cumulative incidence of postoperative candidemia over the 
study period was of 2.03 episodes per 1000 open heart sur-
gery patients. The median age of patients with candidemia 
(interquartile range [IQR]) was 72 (64–78) years, and 55% 
were males. The median time to development of candidemia 
(IQR) was 23 (14–36) days after surgery. Concomitant 
Candida endophthalmitis was diagnosed in 1% of cases 
(1/74). No concomitant Candida endocarditis was ob-
served. Most candidemia episodes were due to C.  albicans 
(48/74, 65%), followed by C.  parapsilosis (10/74, 14%) and 
C. glabrata (7/74, 9%).
Table 1 shows the results of univariable and multivariable 
analyses of factors associated with the development of 
candidemia. In univariable analysis, NYHA class  III 
or IV, previous stroke, low LVEF, higher EuroSCORE 
II score, preoperative mechanical ventilation, hemodi-
alysis therapy, SOFA score at the time of surgery, pre-
vious therapy with cephalosporins, previous therapy with 
carbapenems, previous therapy with fluoroquinolones, and 
multifocal Candida colonization had a statistically signif-
icant association with the development of candidemia. In 
the final multivariable model, NYHA class III or IV (odds 
ratio [OR], 23.81; 95% CI, 5.73–98.95; P < .001), previous 
therapy with carbapenems (OR, 8.87; 95% CI, 2.57–30.67; 
P = .001), and previous therapy with fluoroquinolones 
(OR, 5.73; 95% CI, 1.61–20.41; P = .007) retained an inde-
pendent association.
Thirty-day crude mortality in patients with candidemia 
was 53% (39/74), whereas the crude in-hospital mortality 
of controls was 15% (22/148; chi-square test, P < .001). 
The results of univariable and multivariable analyses of 
factors associated with 30-day mortality in patients with 
candidemia are shown in Table  2. In univariable analysis, 
>5 peri/intraoperative blood transfusions, previous therapy 
with fluoroquinolones, and septic shock at the onset of 
candidemia were associated with increased 30-day mortality. 
Only septic shock, observed in as many as 36% of patients 
with candidemia, retained an independent association with 
the outcome in the final multivariable model (OR, 5.64; 95% 
CI, 1.91–16.63; P = .002).
DISCUSSION
In this retrospective, multicenter, case–control study, high 
NYHA class, previous therapy with carbapenems, and previous 
therapy with fluoroquinolones were associated with the devel-
opment of candidemia after open heart surgery.
Risk factors for developing candidemia after open heart sur-
gery have also been explored by other studies. Michalopoulos 
and colleagues conducted a single-center, case–control study 
in 150 cardiac surgery patients (30 cases with postopera-
tive candidemia and 120 controls without candidemia) [24]. 
Controls were matched to cases according to gender, body mass 
index, agents administered for general anesthesia and for post-
operative sedation, type of employed cardioplegia, and CPB 
technique. Independent predictors of candidemia were me-
chanical ventilation >10 days, hospital-acquired bacterial infec-
tion and/or bacteremia, CPB time >120 minutes, and diabetes 
mellitus [24]. Subsequently, Pasero and colleagues assessed 
risk factors for candidemia in a cohort of patients admitted to 
a cardiac surgery ICU [6]. Among 349 patients, 26 developed 
candidemia. Independent predictors of candidemia were ICU 
length of stay >20 days, total parenteral nutrition, severe sepsis, 
and high simplified acute physiology score (SAPS II), whereas 
no association with development of candidemia was observed 
for CPB time [6].
Similar to Pasero and colleagues, we did not find an associa-
tion between prolonged CPB and development of postoperative 
candidemia (thus apparently not being in line with the hypothesis 
of an enhanced intestinal permeability related to prolonged CPB-
related ischemia, with possible increased risk of translocation of 
bacteria and/or fungi from the intestinal lumen to the blood-
stream) [33–35]. In the interpretation of this results, it should be 
kept in mind that in our study we focused on a subpopulation 
of cardiac surgery patients (ie, those with prolonged postopera-
tive ICU stay). Indeed, candidemia mostly developed late during 
ICU stay (and thus the length of postoperative ICU stay was 
inherently long, also in matched controls), a fact that is in line 
with the well-known role of prolonged hospital stay as a general 
predictor of candidemia [5, 6, 20, 23, 24]. Overall, this may sug-
gest that CPB time is not helpful for discriminating the risk of 
candidemia (absolutely or vs that of bacterial BSI [35]) in car-
diac surgery patients with prolonged ICU stay, that is, in those 
who usually are the most likely to develop candidemia because 
they already express classical, non-surgery-related risk factors. 
For example, our results confirm that the previous administra-
tion of broad-spectrum antibiotics is an important risk factor for 
candidemia in cardiac surgery patients, in line with the results of 
previous studies conducted in more general populations [20, 22, 
23, 36–38], and potentially explained by the disruptive effect that 
previous broad-spectrum antibiotics may have on the human 
microbiota with consequent increased risk of Candida translo-
cation [39]. In addition, we found a high baseline NYHA class 
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to be an independent predictor of postoperative candidemia. 
This finding warrants further investigation, as this predisposing 
factor was not investigated in other studies assessing predictors 
of candidemia in cardiac surgery patients. However, it remains 
reasonable that a high NYHA class may represent a proxy for a 
higher burden of comorbidity or need for more intensive care 
procedures, possibly and generally influencing the risk of post-
operative infections.
As a secondary analysis, we assessed the predictors of 30-day 
mortality in patients with postoperative candidemia. In this 
regard, the independent association we observed between 
septic shock and mortality further confirms the importance of 
the severity of clinical presentation in unfavorably influencing 
the outcome [17]. On the other hand, caution is needed before 
interpreting the absence of other independent predictors of 
mortality in our analysis. For example, early antifungal therapy 
and early CVC removal have been previously indicated as im-
portant predictors of survival [7, 40], and it is worth noting 
that a trend toward improved survival for these 2 factors was 
also appreciable in our univariable results, although it did 
Table 1. Univariable and Multivariable Analyses of Factors Associated With the Development of Candidemia After Open Heart Surgery
Univariable Analysis Multivariable Analysisa
Variable
No. of Cases (%) 
74 (100)
No. of Controls (%) 
148 (100)
Odds Ratio  
(95% CI) P
Odds Ratio  
(95% CI) P
Preoperative and peri/intraoperative variables
 Age, median (IQR), y 72 (64–78) 72 (64–77) 1.00 (0.98–1.03) .932   
 Male gender 41 (55) 99 (67) 0.64 (0.37–1.11) .113   
 Diabetes mellitus 23 (31) 29 (20) 1.80 (0.96–3.39) .067   
 NYHA class III/IV 53 (72) 40 (27) 6.26 (3.21–12.21) <.001 23.81 (5.73–98.95) <.001
 Preoperative serum creatinine >200 μmol/L 29 (39) 42 (28) 1.63 (0.90–2.95) .105   
 COPD 22 (30) 36 (24) 1.34 (0.70–2.56) .372   
 History of immunosuppression 1 (1) 9 (6) 0.20 (0.02–1.64) .133   
 Charlson Comorbidity Index, median (IQR) 5 (3–7) 5 (3–6) 1.08 (0.95–1.23) .232   
 Peripheral vascular disease 14 (19) 27 (18) 1.04 (0.52–2.10) .905   
 Previous stroke 12 (16) 8 (5) 4.00 (1.38–11.57) .010 4.61 (0.68–31.28) .118
 Previous IMA 13 (18) 31 (21) 0.83 (0.42–1.62) .577   
 LVEF, median (IQR), % 50 (37–55) 55 (45–55) 0.97 (0.95–1.00) .031 - .633
 EuroSCORE II 6.61 (3.67–16.43) 3.51 (1.86–8.37) 1.06 (1.02–1.10) .001 - .177
 Preoperative MV 16 (22) 9 (6) 3.56 (1.57–8.05) .002 - .275
 Type of surgery    .073   
  Isolated coronary artery bypass surgery 6 (8) 22 (15) (ref)    
  Isolated valvular surgery 32 (43) 48 (32) 2.43 (0.88–6.71)    
  Surgery of thoracic aorta 26 (35) 41 (28) 2.13 (0.78–5.82)    
  Other/combined procedures 10 (14) 37 (25) 0.93 (0.29–2.97)    
 Pacemaker implantation 2 (3) 10 (7) 0.40 (0.09–1.83) .237   
 CPB time, median (IQR), min 136 (98–208) 136 (92–197) 1.00 (1.00-1.00) .843   
 Aortic cross-clamp time, median (IQR), min 75 (49–120) 87 (58–120) 1.00 (0.99–1.00) .127   
 SOFA score at time of surgery, median (IQR) 4 (1–7) 3 (0–4) 1.19 (1.07–1.34) .002 1.20 (0.99–1.45) .058
 Need for peri/intraoperative blood transfusion 61 (82) 124 (84) 0.85 (0.33–2.22) .854   
 Need for >5 peri/intraoperative blood transfusions 47 (64) 86 (58) 1.56 (0.69–3.52) .288   
Postoperative (during time at risk)
 Central venous catheter >48 h 74 (100) 141 (95) (model not converging) -   
 Total parenteral nutrition >48 h 42 (57) 86 (58) 0.94 (0.50–1.74) .833   
 Hemodialysis >48 h 27 (37) 28 (19) 2.55 (1.32–4.91) .005 - .566
 Therapy with cephalosporins >48 h 18 (24) 12 (8) 4.65 (1.81–11.94) .001 - -
 Therapy with carbapenems >48 h 52 (70) 51 (35) 4.49 (2.37–8.49) <.001 8.87 (2.57–30.67) .001
 Therapy with fluoroquinolones >48 h 49 (66) 51 (35) 5.78 (2.64–12.65) <.001 5.73 (1.61–20.41) .007
 Candida colonization 29 (39) 45 (30) 1.52 (0.83–2.80) .178   
 Candida multifocal colonization (at least 2 sites) 19 (26) 14 (10) 2.95 (1.43–6.12) .004 - .723
 Bacterial BSIb 23 (31) 38 (26) 1.30 (0.69–2.47) .415   
Results are presented as No. (%) unless otherwise indicated. 
Abbreviations: BSI, bloodstream infection; COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary bypass; IMA, acute myocardial infarction; IQR, interquartile range; LVEF, left 
ventricular ejection fraction; MV, mechanical ventilation; NYHA, New York Hearth Association.
aOdds ratio and 95% CI are presented only for variables retained in the final multivariable model (ie, NYHA class  III/IV, previous stroke, SOFA score at time of surgery, therapy with 
fluoroquinolones >48 hours, therapy with carbapenems >48 hours).
bCoagulase-negative staphylococci (n = 24), Klebsiella spp. (n = 8), Staphylococcus aureus (n = 6), Enterobacter spp. (n = 3), Pseudomonas spp. (n = 3), Enterococcus spp. (n = 2), and other 
bacteria with lower frequencies (n = 15).
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Table 2. Univariable and Multivariable Analyses of Factors Associated With 30-Day Mortality in Open Heart Surgery Patients With Postoperative 
Candidemia
Univariable Analysis Multivariable Analysisb
Variable
Nonsurvivors, No. (%) 
39 (100)
Survivors, No. (%) 
35 (100)
Odds Ratio  
(95% CI) P
Odds Ratio  
(95% CI) P
Preoperative and peri/intraoperative variables
 Age, median (IQR), y 75 (67–79) 68 (60–76) 1.03 (0.99–1.08) .129   
 Male gender 21 (54) 20 (57) 0.88 (0.35–2.19) .776   
 Diabetes mellitus 11 (28) 12 (34) 0.75 (0.28–2.02) .573   
 NYHA class III/IV 29 (74) 24 (69) 1.33 (0.48–3.66) .582   
 Preoperative serum creatinine >200 μmol/L 17 (44) 12 (34) 1.48 (0.58–3.80) .414   
 COPD 12 (31) 10 (29) 1.11 (0.41–3.02) .836   
 History of immunosuppression 1 (3) 0 (0) (model not converging) -   
 Charlson Comorbidity Index, median (IQR) 5 (3–7) 5 (2–6) 1.09 (0.90–1.32) .390   
 Peripheral vascular disease 7 (18) 7 (20) 0.88 (0.27–2.80) .822   
 Previous stroke 7 (18) 5 (14) 1.31 (0.38–4.59) .670   
 Previous IMA 10 (26) 3 (9) 3.68 (0.92–14.69) .065   
 LVEF, median (IQR), % 50 (35–55) 48 (39–55) 1.00 (0.96–1.04) .984   
 EuroSCORE II 13.57 (4.07–21.93) 4.57 (3.43–10.34) 1.05 (1.00–1.10) .052   
 Preoperative MV 10 (26) 6 (17) 1.67 (0.54–5.19) .378   
 Type of surgery    .898   
  Isolated coronary artery bypass surgery 4 (10) 2 (6) (ref)    
  Isolated valvular surgery 16 (41) 16 (46) 0.50 (0.08–3.13)    
  Surgery of thoracic aorta 14 (36) 12 (34) 0.58 (0.09–3.76)    
  Other/combined procedures 5 (13) 5 (14) 0.50 (0.06–4.09)    
 Pacemaker implantation 1 (3) 1 (3) 0.90 (0.05–14.86) .938   
 CPB time, median (IQR), min 136 (98–198) 137 (93–213) 1.00 (1.00-1.00) .652   
 Aortic cross-clamp time, median (IQR), min 73 (51–110) 89 (49–140) 1.00 (0.99–1.01) .603   
 SOFA score at time of surgery, median (IQR) 4 (1–7) 3 (1–6) 1.02 (0.89–1.17) .749   
 Need for peri/intraoperative blood transfusion 32 (82) 29 (83) 0.95 (0.29–3.14) .928   
 Need for >5 peri/intraoperative blood transfusions 29 (74) 18 (51) 2.74 (1.03–7.28) .043 - .151
Postoperative variables (during time at risk)
 Central venous catheter >48 h 39 (100) 35 (100) - -   
 Total parenteral nutrition >48 h 25 (64) 17 (49) 1.89 (0.75–4.80) .180   
 Hemodialysis >48 h 16 (41) 11 (31) 1.52 (0.58–3.95) .393   
 Therapy with cephalosporins >48 h 10 (26) 8 (23) 1.16 (0.40–3.38) .781   
 Therapy with carbapenems >48 h 26 (67) 26 (74) 0.69 (0.25–1.90) .475   
 Therapy with fluoroquinolones >48 h 30 (77) 19 (54) 2.81 (1.03–7.62) .043 - .115
 Candida colonization 13 (33) 16 (46) 0.59 (0.23–1.52) .278   
 Candida multifocal colonization (≥2 sites) 9 (23) 10 (29) 0.75 (0.26–2.13) .590   
 Bacterial BSIb 9 (23) 14 (40) 0.45 (0.17–1.23) .120   
Candidemia-related variables
 Septic shock 21 (54) 6 (17) 5.64 (1.91–16.63) .002 5.64 (1.91–16.63) .002
 Causative Candida species    .184   
  albicans 28 (74) 20 (59) (ref)    
  Non-albicansc 10 (26) 14 (41) 0.51 (0.19–1.38)    
 Early antifungal therapy (within 48 hd) 13 (33) 16 (46) 0.59 (0.23–1.52) .278   
 Early CVC removal (within 48 hd) 13 (33) 14 (40) 0.75 (0.29–1.94) .552   
Results are presented as No. (%) unless otherwise indicated. 
Abbreviations: BSI, bloodstream infection; COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary bypass; CVC, central venous catheter; IMA, acute myocardial infarction; 
IQR, interquartile range; LVEF, left ventricular ejection fraction; MV, mechanical ventilation; NYHA, New York Hearth Association.
aOdds ratio and 95% CI are presented only for the variables retained in the final multivariable model (ie, septic shock).
bCoagulase-negative staphylococci (n = 8), Klebsiella spp. (n = 5), Pseudomonas spp. (n = 3), Staphylococcus aureus (n = 2), other bacteria with lower frequencies (n = 5).
cTwo nontyped species were not included in the comparison albicans vs non-albicans species. Typed non-albicans species were as follows: C. parapsilosis (n = 10), C. glabrata (n = 7), 
C. tropicalis (n = 3), C. krusei (n = 2), C. dubliniensis (n = 1), C. sake (n = 1).
dAfter the onset of candidemia (ie, the day when the first positive blood culture for Candida spp. was drawn).
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not reach statistical significance (possibly because of reduced 
power). Finally, it is of note that the low cumulative incidence 
of candidemia we found was similar to that observed in surgical 
ICUs in a recent European multicenter study [17], possibly re-
flecting the presence in the denominator of a high number of 
patients with short postoperative ICU stay and consequent low 
risk of candidemia.
This study has some important limitations. The most important 
are related to its retrospective nature and mainly consist of pos-
sible information biases (eg, we did not systematically register the 
number of performed ophthalmologist evaluations and echocar-
diograms in cases, although they are considered standard proced-
ures in our centers). Another limitation is that we were unable to 
retrospectively collect sufficient data and/or adjustments for time 
at risk for some postoperative intensive care procedures (eg, use of 
intra-aortic balloon pump) and some postoperative noninfectious 
complications (eg, reoperations for bleeding) that may have influ-
enced the risk of infection. Two other important limitations are 
the lack of long-term follow-up in survivors of candidemia [26] 
and the use of a single control group instead of 2 different con-
trol groups to separately assess (i) the predictors of candidemia vs 
no infection and (ii) the predictors of candidemia vs bacteremia. 
Finally, although increased with respect to previous studies, the 
power of our primary analysis remains somewhat suboptimal; 
thus we may have failed to detect other true associations that could 
be clinically relevant. Nonetheless, to our knowledge this is the lar-
gest cohort of candidemic cardiac surgery patients (n = 74) em-
ployed for assessing the risk of postoperative candidemia, and it 
may add valuable information to the literature, complementary to 
that of previous studies with more limited sample sizes.
In conclusion, previous broad-spectrum antibiotic therapy 
and high NYHA class were independent predictors of 
candidemia in cardiac surgery patients with prolonged post-
operative ICU stay, whereas no association between prolonged 
CPB time and candidemia was observed in the present case–
control study. Further studies are needed to explore the pos-
sible role of CPB-related ischemia in influencing the risk of 
candidemia episodes occurring early after surgery.
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